Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer
Shots:
- The new pooled exploratory analysis from the P-III (MONALEESA-2/3/7) study evaluates Kisqali + ET vs ET alone in patients with HR+/HER2- aBC patients with visceral metastases
- The results showed a 1yr. OS benefits in harder-to-treat populations while maintaining or improving QoL across 3 P-III trials regardless of patient or disease characteristics, patients achieved an m-OS of 62.7mos. vs 52.1mos. in patients with visceral metastases incl. liver metastases and multiple metastatic sites. The results will be presented at ESMO 2022
- In patients with liver metastases, m-OS was 44.2mos. vs 38.1mos. while 57.7mos. vs 49.3mos. in patients with visceral metastases in ≥3 organs as 1L treatment with Kisqali + ET
Ref: Novartis | Image: Novartis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
